L1EPO, a Novel Podophyllotoxin Derivative Overcomes P-Glycoprotein-Mediated Multidrug Resistance in K562/A02 Cell Line(Pharmacology)

    • CHEN Hong
    • Medical College of Chinese People's Armed Police Forces:Tianjin Key Laboratory for Biomarkers of Occupational and Environmental Hazard
    • WANG Jing
    • Medical College of Chinese People's Armed Police Forces
    • ZHANG Jingze
    • Medical College of Chinese People's Armed Police Forces
    • WANG Yizheng
    • Medical College of Chinese People's Armed Police Forces:Tianjin Key Laboratory for Biomarkers of Occupational and Environmental Hazard

    • CAO Bo
    • Medical College of Chinese People's Armed Police Forces
    • BAI Shufang
    • Medical College of Chinese People's Armed Police Forces
    • YU Peng-Fei
    • Key Lab of New Drugs Design and Discovery of Liaoning Province, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University
    • BI Wenchao
    • Medical College of Chinese People's Armed Police Forces

    • XIE Wenli
    • Medical College of Chinese People's Armed Police Forces

抄録

The ineffectiveness of anticancer drugs is frequently observed in cancer chemotherapy. The resistance of tumor cells to various cytotoxic drugs is defined as multidrug resistance (MDR). The purpose of our present study was to investigate the inhibitory effects of L1EPO synthesized by our group on P-glycoprotein (P-gp)-mediated MDR in K562/A02 and KBv200 cell lines, which expressed high levels of P-gp. Both the cytotoxicity of the compound and its ability to inhibit K562/A02 and KBv200 cells were determined by sulforhodamine B sodium salt (SRB) assay. Morphologic apoptosis was detected by Hoechst33342 staining assay. Reverse transcriptase-polymerase chain reaction (RT-PCR) was used to detect mdr-1 gene transcription, and Western blot assay was used to assess P-gp expression. Interestingly, we found that the K562/A02 cell line was rendered resistant toward Adriamycin but not towards L1EPO when compared with the parental cells. Furthermore, L1EPO could down-regulate the mdr-1 gene, and it reduced the expression of P-gp and displayed a perfect dose dependence. Moreover, it had less cytotoxicity in normal human cell lines (fibroblast, VEC), GI_<50>>10μmol/l. Consequently, L1EPO has the potential to overcome P-glycoprotein-mediated MDR in the K562/A02 cell line.

収録刊行物

Biological & pharmaceutical bulletin   [巻号一覧]

Biological & pharmaceutical bulletin 32(4), 609-613, 2009-04-01  [この号の目次]

公益社団法人日本薬学会

参考文献:  16件

参考文献を見るにはログインが必要です。ユーザIDをお持ちでない方は新規登録してください。

プレビュー

プレビュー

各種コード

  • NII論文ID(NAID) :
    110007160694
  • NII書誌ID(NCID) :
    AA10885497
  • 本文言語コード :
    ENG
  • 資料種別 :
    ART
  • ISSN :
    09186158
  • NDL 記事登録ID :
    10194238
  • NDL 雑誌分類 :
    ZS51(科学技術--薬学)
  • NDL 請求記号 :
    Z53-V41
  • 収録DB :
    CJP書誌  NDL  NII-ELS  J-STAGE